Paula A. Johnson

CIK: 0001341161

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

MAZE

Maze Therapeutics, Inc.

Director

JNJ

JOHNSON & JOHNSON

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

MAZE
Maze Therapeutics, Inc.
Aug 13, 2026
Award(A)
Stock Option (Right to Buy)
Direct
36K shares-
JNJ
JOHNSON & JOHNSON
Apr 23, 2026
Award(A)
Deferred Share Units
Direct
975 shares-
JNJ
JOHNSON & JOHNSON
Apr 24, 2025
Award(A)
Deferred Share Units
Direct
1.3K shares-
JNJ
JOHNSON & JOHNSON
Aug 23, 2023
Disposition(D)
Direct
11 shares-

		Type	Shares	Price		Ownership
Aug 13, 2026	MAZE Maze Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	36,000	-	-	Direct
Apr 23, 2026	JNJ JOHNSON & JOHNSON	Award(A) Deferred Share Units	975	-	-	Direct
Apr 24, 2025	JNJ JOHNSON & JOHNSON	Award(A) Deferred Share Units	1,316	-	-	Direct
Aug 23, 2023	JNJ JOHNSON & JOHNSON	Disposition(D)	11	-	$0	Direct

1-4 of 4 transactions

About Johnson Paula A

Johnson Paula A (SEC CIK 0001341161) files insider reports with the SEC as Director of Maze Therapeutics, Inc. (MAZE) and Director of JOHNSON & JOHNSON (JNJ).

Signal8 holds 5 ownership filings by Johnson Paula A (1 Form 3, 3 Form 4, 1 Form 5), filed between Apr 28, 2025 and Aug 17, 2026. Those filings report 4 transactions, from Aug 23, 2023 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Johnson Paula A's filings is in NEW BRUNSWICK, NJ.

Recent filings by Johnson Paula A

Aug 13, 2026: Grant or award of MAZE derivative securities (Form 4, code A).
Apr 23, 2026: Grant or award of JNJ derivative securities (Form 4, code A).
Apr 24, 2025: Grant or award of JNJ derivative securities (Form 4, code A).
Aug 23, 2023: Disposition to issuer transaction of JNJ shares (Form 5, code D).

Other insiders filing for Maze Therapeutics, Inc. (MAZE)

Dandekar Atul, CSBO
Coloma Jason V, Chief Executive Officer
Bernstein Harold, President, R&D & CMO
Courtney Phillips, GC and Corp. Secretary
Kornowski Sophie, Director
SPIEGELMAN DANIEL K, Director

How to read Form 4 transaction codes